세계의 인간화 마우스 및 쥐 모델 시장 예측(-2030년) : 유형별, 최종사용자별, 용도별, 지역별

The global humanized mouse and rat model market is anticipated to reach USD 409.8 million in 2030 from USD 276.2 million in 2025, with a significant CAGR of 8.2%. The market is growing strongly at a high CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players will likely witness healthy growth opportunities due to technological advancements, new drug discovery techniques, patent expirations, and rising demand for specialized testing services among end users.

"Humanized mouse model segment dominated the type segment in 2024"

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2024, humanized mouse models will have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with the fastest CAGR through the forecast period. An increase in demand for cell-based humanized mouse models has contributed to the segment's growth. These models are utilized in various applications, including the analysis of the safety and effectiveness of potential new drugs and in long-term studies in immuno-oncology, infectious diseases, and graft-versus-host disease.

"The immunology & infectious diseases segment accounted for the second largest share of the market in 2024"

The humanized mouse and rat model market is segmented based on application into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes.

"Pharmaceutical & Biotechnology Companies will likely record the highest CAGR during the forecast period"

Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the humanized mouse and rat model market is due to the rising expenditure for innovative drug development and the growing preference for personalized medicine. However, the CROs & CDMOs segment is expected to register the highest growth during the forecast period due to the increasing number of pharmaceutical & biotechnology companies outsourcing preclinical studies and research activities for drug development to this end user segment.

"US to record the highest CAGR during the forecast period"

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the humanized mouse and rat model market in 2024 and is estimated to continue dominating during the forecast period. The US leads the North American market, driven by the presence of key players. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth.

In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the humanized mouse and rat model market.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
• By Designation: C-level Executives - 45%, Directors - 30%, and Others - 25%
• By Region: North America - 45%, Europe - 30%, Asia Pacific - 20%, Latin America - 3% and Middle East & Africa - 2%

Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), JSR Corporation (US) (Crown Biosciences), Champions Oncology, Inc. (US), CLEA Japan Inc. (Japan), genOway (France), Inotiv (US), Janvier Labs (France), Altogen Labs (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), Reaction Biology (US), Harbour BioMed (Netherlands), Oncodesign Services (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure bioServices (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US) are some of the key players in the humanized mouse and rat model market.

Research Coverage:

Humanized mouse and rat model market report is segmented based on type {[(humanized mouse models {genetic humanized mouse models and cell-based humanized mouse models (CD34 humanized mouse models, PBMC humanized mouse models, and BLT humanized mouse models)]} and humanized rat models), application (oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications, end user (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East, Africa).

The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the humanized mouse and rat model market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This includes information about recent product launches, collaborations, acquisitions, and humanized mouse and rat model market developments.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the humanized mouse and rat model and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising use of humanized models in drug discovery research, emerging preclinical applications of humanized mouse models, government-funded initiatives for cancer research, and increasing R&D activities in the pharmaceutical & biotechnology industry), restraints (introduction of FDA Modernization Act 2.0/3.0, stringent regulatory compliance for ethical use of animal models), opportunities (growing preference for humanized PDX models, emergence of CRISPR in biomedical research), and challenges (alternatives for animal testing, limitations of humanized mouse models) influencing market growth.
• Product Development/Innovation: Detailed insights on upcoming technologies in humanized mouse and rat models, research and development activities, and new product launches in the humanized mouse and rat model market.
• Market Development: Comprehensive information about lucrative markets-the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Inotiv (US), and genOway (France).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS AND EXCLUSIONS
• 1.4 STUDY SCOPE
  • 1.4.1 MARKET SEGMENTATION AND REGIONS COVERED
  • 1.4.2 YEARS CONSIDERED
  • 1.4.3 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
  • 2.2.2 SEGMENTAL MARKET ESTIMATION
• 2.3 GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW
• 4.2 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY, 2024
• 4.3 HUMANIZED MOUSE AND RAT MODEL MARKET, BY KEY COUNTRY
• 4.4 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising use of humanized models in drug discovery research
    • 5.2.1.2 Emerging preclinical applications of humanized mouse models
    • 5.2.1.3 Government-funded initiatives for cancer research
    • 5.2.1.4 Increasing R&D activities in pharmaceutical & biotechnology industry
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Introduction of FDA Modernization Act 2.0/3.0
    • 5.2.2.2 Stringent regulatory compliance for ethical use of animal models
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing preference for humanized PDX models
    • 5.2.3.2 Emergence of CRISPR in biomedical research
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Alternative methods for animal testing
    • 5.2.4.2 Limitations of humanized mouse models
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 CRISPR-Cas9
    • 5.9.1.2 Tissue engineering
    • 5.9.1.3 In vivo imaging
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 3D cell culture
    • 5.9.2.2 Organs-on-Chips
    • 5.9.2.3 Biomarker discovery
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Proteomics
    • 5.9.3.2 Microfluidics
    • 5.9.3.3 Regenerative medicine
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 REGULATORY LANDSCAPE
  • 5.13.1 REGULATORY FRAMEWORK
  • 5.13.2 NORTH AMERICA
  • 5.13.3 EUROPE
  • 5.13.4 ASIA PACIFIC
    • 5.13.4.1 China
    • 5.13.4.2 Japan
    • 5.13.4.3 India
    • 5.13.4.4 Australia
  • 5.13.5 LATIN AMERICA
  • 5.13.6 MIDDLE EAST & AFRICA
  • 5.13.7 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.14 PORTER'S FIVE FORCES ANALYSIS
  • 5.14.1 THREAT OF NEW ENTRANTS
  • 5.14.2 THREAT OF SUBSTITUTES
  • 5.14.3 BARGAINING POWER OF SUPPLIERS
  • 5.14.4 BARGAINING POWER OF BUYERS
  • 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 KEY BUYING CRITERIA, BY END USER
• 5.16 IMPACT OF AI ON HUMANIZED MOUSE AND RAT MODEL MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 MARKET POTENTIAL OF AI IN HUMANIZED MOUSE AND RAT MODELS
  • 5.16.3 AI USE CASES
  • 5.16.4 KEY COMPANIES IMPLEMENTING AI
  • 5.16.5 FUTURE OF GENERATIVE AI IN HUMANIZED MOUSE AND RAT MODEL MARKET

6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 HUMANIZED MOUSE MODELS
  • 6.2.1 GENETIC HUMANIZED MOUSE MODELS
    • 6.2.1.1 Advancements in genetical engineering technologies to drive market
  • 6.2.2 CELL-BASED HUMANIZED MOUSE MODELS
    • 6.2.2.1 CD34 humanized mouse models
      • 6.2.2.1.1 Rising demand for stem cell therapy to propel market
    • 6.2.2.2 PBMC humanized mouse models
      • 6.2.2.2.1 Growing prevalence of infectious diseases to boost demand
    • 6.2.2.3 BLT humanized mouse models
      • 6.2.2.3.1 Surge in HIV cases to drive market
• 6.3 HUMANIZED RAT MODELS
  • 6.3.1 PREFERENCE FOR SRG RAT MODELS FOR RESEARCH STUDIES WITH LARGE SAMPLE SIZE SUPPORTS THE SEGMENT GROWTH

7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

• 7.1 INTRODUCTION
• 7.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 7.2.1 GROWING ADOPTION OF HU-MICE MODELS IN VACCINE DEVELOPMENT TO BOOST SEGMENT GROWTH
• 7.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS
  • 7.3.1 OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET
• 7.4 ACADEMIC & RESEARCH INSTITUTES
  • 7.4.1 SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET

8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 ONCOLOGY
  • 8.2.1 UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO DRIVE MARKET
• 8.3 IMMUNOLOGY AND INFECTIOUS DISEASES
  • 8.3.1 DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET
• 8.4 NEUROSCIENCE
  • 8.4.1 RISING INCIDENCE OF CNS DISORDERS TO DRIVE MARKET
• 8.5 TOXICOLOGY
  • 8.5.1 INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH
• 8.6 HEMATOPOIESIS
  • 8.6.1 RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET
• 8.7 OTHER APPLICATIONS

9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 Growing research initiatives on mAbs and biosimilars to drive market
  • 9.2.3 CANADA
    • 9.2.3.1 Government initiatives on stem cell research to drive market
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK OF EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Rising pharmaceutical R&D expenditure to drive market
  • 9.3.3 UK
    • 9.3.3.1 Growing investments in cancer research to drive market
  • 9.3.4 FRANCE
    • 9.3.4.1 Rising initiatives for genomics research to support market growth
  • 9.3.5 ITALY
    • 9.3.5.1 Robust pharmaceutical production to fuel market
  • 9.3.6 SPAIN
    • 9.3.6.1 Rising growth in biotech industry to drive market
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 High growth in pharmaceutical industry to drive market
  • 9.4.3 JAPAN
    • 9.4.3.1 Growing research collaborations among pharmaceutical companies to drive market
  • 9.4.4 INDIA
    • 9.4.4.1 Growth in biotech industry to drive market
  • 9.4.5 SOUTH KOREA
    • 9.4.5.1 Rising government-funded investments for pharmaceutical R&D to drive market
  • 9.4.6 AUSTRALIA
    • 9.4.6.1 Rising biomedical research projects to drive market
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET
  • 9.5.2 MACROECONOMIC OUTLOOK OF LATIN AMERICA
• 9.6 MIDDLE EAST
  • 9.6.1 GROWING PHARMACEUTICAL MARKET IN COUNTRIES TO SUPPORT MARKET GROWTH
  • 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
• 9.7 AFRICA
  • 9.7.1 GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
  • 9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET
• 10.3 REVENUE ANALYSIS, 2020-2024
• 10.4 MARKET SHARE ANALYSIS, 2024
  • 10.4.1 HUMANIZED MOUSE AND RAT MODEL MARKET
• 10.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 10.5.1 FINANCIAL METRICS
• 10.6 BRAND/PRODUCT COMPARISON
• 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.7.1 STARS
  • 10.7.2 EMERGING LEADERS
  • 10.7.3 PERVASIVE PLAYERS
  • 10.7.4 PARTICIPANTS
  • 10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.7.5.1 Company footprint
    • 10.7.5.2 Region footprint
    • 10.7.5.3 Type footprint
    • 10.7.5.4 Application footprint
• 10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.8.1 PROGRESSIVE COMPANIES
  • 10.8.2 RESPONSIVE COMPANIES
  • 10.8.3 DYNAMIC COMPANIES
  • 10.8.4 STARTING BLOCKS
  • 10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
    • 10.8.5.1 Detailed list of key startups/SMEs
    • 10.8.5.2 Competitive benchmarking of key startups/SMEs
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES & APPROVALS
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 CHARLES RIVER LABORATORIES
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
      • 11.1.1.3.2 Other developments
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 THE JACKSON LABORATORY
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses and competitive threats
  • 11.1.3 INOTIV
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 GENOWAY
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Other developments
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses and competitive threats
  • 11.1.5 TACONIC BIOSCIENCES, INC.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches
      • 11.1.5.3.2 Expansions
  • 11.1.6 JSR CORPORATION
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Deals
      • 11.1.6.3.2 Expansions
  • 11.1.7 CHAMPIONS ONCOLOGY, INC.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
  • 11.1.8 JANVIER LABS
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Deals
  • 11.1.9 VITALSTAR BIOTECHNOLOGY
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
  • 11.1.10 INGENIOUS TARGETING LABORATORY
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
  • 11.1.11 HARBOUR BIOMED
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Deals
  • 11.1.12 ONCODESIGN SERVICES
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
  • 11.1.13 PHARMATEST SERVICES
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 OZGENE PTY LTD.
  • 11.2.2 CLEA JAPAN, INC.
  • 11.2.3 ALTOGEN LABS
  • 11.2.4 REACTION BIOLOGY
  • 11.2.5 TRANSCURE BIOSERVICES
  • 11.2.6 CYAGEN
  • 11.2.7 ARAGEN LIFE SCIENCES LTD.
  • 11.2.8 BIOCYTOGEN
  • 11.2.9 GEMPHARMATECH

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS